ADIAL PHARMACEUTICALS, INC. Quarterly Operating Income (Loss) in USD from Q2 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Adial Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2017 to Q3 2024.
  • Adial Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$2.21M, a 62.9% decline year-over-year.
  • Adial Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$6.89M, a 36.6% increase from 2022.
  • Adial Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$10.9M, a 43.7% increase from 2021.
  • Adial Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$19.3M, a 76.5% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$2.21M -$854K -62.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$2.29M -$810K -54.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q4 2023 -$6.89M -$1.13M +$870K +43.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-01
Q3 2023 -$7.76M -$1.36M +$1.2M +46.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$8.95M -$1.48M +$1.77M +54.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$10.7M -$2.92M +$138K +4.52% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-12
Q4 2022 -$10.9M -$2M +$3.98M +66.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 -$14.8M -$2.55M +$1.51M +37.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$16.3M -$3.24M +$1.16M +26.3% Apr 1, 2022 Jun 30, 2022 10-Q/A 2023-10-30
Q1 2022 -$17.5M -$3.06M +$1.78M +36.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 -$19.3M -$5.98M -$2.51M -72.3% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$16.8M -$4.06M -$725K -21.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$16.1M -$4.4M -$2.58M -142% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$13.5M -$4.84M -$2.54M -110% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$10.9M -$3.47M -$1.38M -66% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-28
Q3 2020 -$9.55M -$3.34M -$1.59M -91.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$7.96M -$1.82M +$340K +15.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$8.3M -$2.3M -$51K -2.27% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 -$8.24M -$2.09M -$1M -91.8% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-22
Q3 2019 -$7.24M -$1.75M +$2.07M +54.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 -$9.31M -$2.16M -$418K -24% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$8.9M -$2.25M -$1.91M -562% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 -$6.99M -$1.09M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-20
Q3 2018 -$3.82M -$3.55M -1354% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$1.74M -$1.5M -621% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 -$340K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
Q3 2017 -$262K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-14
Q2 2017 -$241K Apr 1, 2017 Jun 30, 2017 10-Q 2018-09-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.